Figure 2.

Cumulative number of severe exacerbations in each study group over the course of 50 weeks treatment with mepolizumab or placebo. Mean number of exacerbations per subject over the course of the 50-week treatment period was 2.0 in the mepolizumab group, compared with 3.4 in the placebo group (relative risk, 0.57; 95% confidence interval, 0.32 to 0.92; P = 0.02). Reproduced from Haldar et al with permission [27]. Copyright (c) Massachusetts Medical Society.